Area of research
Pulmonary and Respiratory Medicine · Molecular Biology
Research interest
Research focused on Nausea and Cancer research, with related work in Fibroblast growth factor receptor, Triple-negative breast cancer, Insertional mutagenesis. Notable publications include 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma', 'Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition', and 'Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf −/− mouse model'.
Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression
Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf <sup>−/−</sup> mouse model
ACTR-74. A PHASE IB/II, OPEN-LABEL, MULTICENTER STUDY OF CAPMATINIB (INC280) ALONE AND IN COMBINATION WITH BUPARLISIB (BKM120) IN ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA
Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma